ID   NCEB-1
AC   CVCL_1875
SY   Nceb-1; NCEB1; NCEB
DR   ATCC; CRL-3005
DR   BioSample; SAMN03471708
DR   cancercelllines; CVCL_1875
DR   Cosmic; 1070711
DR   Cosmic; 2296994
DR   DSMZ; ACC-721
DR   DSMZCellDive; ACC-721
DR   GEO; GSM95564
DR   GEO; GSM95569
DR   GEO; GSM104461
DR   GEO; GSM115803
DR   IARC_TP53; 25019
DR   Progenetix; CVCL_1875
DR   Wikidata; Q54907697
RX   DOI=10.1016/B978-0-12-221970-2.50457-5;
RX   PubMed=2848599;
RX   PubMed=7849311;
RX   PubMed=12169673;
RX   PubMed=16183118;
RX   PubMed=16448697;
RX   PubMed=16960149;
RX   PubMed=25315077;
RX   PubMed=28196595;
WW   https://tcpaportal.org/mclp/
CC   Part of: Lymphoma Research Foundation Mantle Cell Lymphoma cell bank (LRF MCL cell bank).
CC   Part of: MD Anderson Cell Lines Project.
CC   Doubling time: 72-96 hours (PubMed=2848599); 19 hours (PubMed=25315077); ~50-70 hours (DSMZ=ACC-721).
CC   Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Glu221Lys (c.661G>A); ClinVar=VCV000184647; Zygosity=Unspecified (PubMed=16448697).
CC   Transformant: NCBI_TaxID; 10376; Epstein-Barr virus (EBV).
CC   Omics: Array-based CGH.
CC   Omics: Protein expression by reverse-phase protein arrays.
CC   Omics: SNP array analysis.
CC   Omics: Transcriptome analysis by microarray.
CC   Caution: Established from a 57 year old male patient but contains some intact murine chromosomes (ATCC; PubMed=16448697) so should be considered as an hybrid cell line.
CC   Derived from site: In situ; Peripheral blood; UBERON=UBERON_0000178.
ST   Source(s): ATCC; DSMZ
ST   Amelogenin: X
ST   CSF1PO: 12,13
ST   D13S317: 12
ST   D16S539: 9,10
ST   D18S51: 13,16
ST   D19S433: 12,15
ST   D21S11: 30,31
ST   D2S1338: 19,20
ST   D3S1358: 15,17
ST   D5S818: 9,11
ST   D7S820: 10,11
ST   D8S1179: 13,15
ST   FGA: 20,26
ST   Penta D: 12,13
ST   Penta E: 7
ST   TH01: 6,9.3
ST   TPOX: 11
ST   vWA: 14,18
DI   NCIt; C4337; Mantle cell lymphoma
DI   ORDO; Orphanet_52416; Mantle cell lymphoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
OX   NCBI_TaxID=10090; ! Mus musculus (Mouse)
CA   Hybrid cell line
DT   Created: 04-04-12; Last updated: 05-10-23; Version: 24
//
RX   DOI=10.1016/B978-0-12-221970-2.50457-5;
RA   Drexler H.G.;
RT   "The leukemia-lymphoma cell line factsbook.";
RL   (In) ISBN 9780122219702; pp.1-733; Academic Press; London (2001).
//
RX   PubMed=2848599; DOI=10.1182/blood.V72.6.2026.2026;
RA   Saltman D.L., Cachia P.G., Dewar A.E., Ross F.M., Krajewski A.S.,
RA   Ludlam C., Steel C.M.;
RT   "Characterization of a new non-Hodgkin's lymphoma cell line (NCEB-1)
RT   with a chromosomal (11:14) translocation [t(11:14)(q13;q32)].";
RL   Blood 72:2026-2030(1988).
//
RX   PubMed=7849311; DOI=10.1182/blood.V85.4.893.bloodjournal854893;
RA   Stranks G., Height S.E., Mitchell P., Jadayel D.M., Yuille M.A.R.,
RA   De Lord C., Clutterbuck R.D., Treleaven J.G., Powles R.L.,
RA   Nacheva E., Oscier D.G., Karpas A., Lenoir G.M., Smith S.D.,
RA   Millar J.L., Catovsky D., Dyer M.J.S.;
RT   "Deletions and rearrangement of CDKN2 in lymphoid malignancy.";
RL   Blood 85:893-901(1995).
//
RX   PubMed=12169673; DOI=10.1016/S1525-1578(10)60693-9;
RA   Robetorye R.S., Bohling S.D., Morgan J.W., Fillmore G.C., Lim M.S.,
RA   Elenitoba-Johnson K.S.J.;
RT   "Microarray analysis of B-cell lymphoma cell lines with the
RT   t(14;18).";
RL   J. Mol. Diagn. 4:123-136(2002).
//
RX   PubMed=16183118; DOI=10.1016/j.leukres.2005.08.016;
RA   Tucker C.A., Bebb G., Klasa R.J., Chhanabhai M., Lestou V.S.,
RA   Horsman D.E., Gascoyne R.D., Wiestner A., Masin D., Bally M.,
RA   Williams M.E.;
RT   "Four human t(11;14)(q13;q32)-containing cell lines having classic and
RT   variant features of mantle cell lymphoma.";
RL   Leuk. Res. 30:449-457(2006).
//
RX   PubMed=16448697; DOI=10.1016/j.leukres.2005.11.013;
RA   Camps J., Salaverria I., Garcia M.J., Prat E., Bea S., Pole J.C.M.,
RA   Hernandez L., Del Rey J., Cigudosa J.C., Bernues M., Caldas C.,
RA   Colomer D., Miro R., Campo E.;
RT   "Genomic imbalances and patterns of karyotypic variability in mantle-cell
RT   lymphoma cell lines.";
RL   Leuk. Res. 30:923-934(2006).
//
RX   PubMed=16960149; DOI=10.1182/blood-2006-06-026500;
RA   Mestre-Escorihuela C., Rubio-Moscardo F., Richter J.A., Siebert R.,
RA   Climent J., Fresquet V., Beltran E., Agirre X., Marugan I., Marin M.,
RA   Rosenwald A., Sugimoto K.-j., Wheat L.M., Karran E.L., Garcia J.F.,
RA   Sanchez-Verde L., Prosper F., Staudt L.M., Pinkel D., Dyer M.J.S.,
RA   Martinez-Climent J.A.;
RT   "Homozygous deletions localize novel tumor suppressor genes in B-cell
RT   lymphomas.";
RL   Blood 109:271-280(2007).
//
RX   PubMed=25315077; DOI=10.3109/10428194.2014.970548;
RA   Fogli L.K., Williams M.E., Connors J.M., Reid Y.A., Brown K.,
RA   O'Connor O.A.;
RT   "Development and characterization of a Mantle Cell Lymphoma Cell Bank
RT   in the American Type Culture Collection.";
RL   Leuk. Lymphoma 56:2114-2122(2015).
//
RX   PubMed=28196595; DOI=10.1016/j.ccell.2017.01.005;
RA   Li J., Zhao W., Akbani R., Liu W.-B., Ju Z.-L., Ling S.-Y., Vellano C.P.,
RA   Roebuck P., Yu Q.-H., Eterovic A.K., Byers L.A., Davies M.A., Deng W.-L.,
RA   Gopal Y.N.V., Chen G., von Euw E.M., Slamon D.J., Conklin D.,
RA   Heymach J.V., Gazdar A.F., Minna J.D., Myers J.N., Lu Y.-L., Mills G.B.,
RA   Liang H.;
RT   "Characterization of human cancer cell lines by reverse-phase protein
RT   arrays.";
RL   Cancer Cell 31:225-239(2017).
//